NIH to open long COVID clinical trials to study sleep disturbances, exercise intolerance, and post exertional malaise


Part of the NIH RECOVER Initiative, trials will test four treatments. The National Institutes of Health (NIH) will launch clinical trials to investigate potential treatments for long-term symptoms after COVID-19…[...]

Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection


Authors: Bruce K. Patterson, 1 , * Edgar B. Francisco, 1 Ram Yogendra, 2 et. al., Front Immunol. 2021; 12: 746021.Published online 2022 Jan 10. doi: 10.3389/fimmu.2021. 746021PMCID: PMC8784688PMID: 35082777 Abstract The recent COVID-19 pandemic is a treatment challenge in the acute…[...]

Mesenteric Panniculitis and COVID-19: A Rare Association


Authors: Israa A Alyousef,1Zainab A Alsaileek,1Manar A Alabdulsalam,1et. al. Cureus. 2022 Jan; 14(1): e21314. . doi: 10.7759/cureus.21314 PMCID: PMC8849467PMID: 35186573 Abstract Coronavirus disease 2019 (COVID-19) typically involves the respiratory system, but gastrointestinal involvement is common.…[...]

Role of 2-Deoxy-D-Glucose in Enhancing the Efficacy of Standard of Care for Moderate to Severe COVID-19: A Comparative Analysis of Clinical Outcomes


Triven Sagar Sandepogu • Chennakesavulu Dara • Saranya Mallamgunta •, et. al. DOI: 10.7759/cureus.73993  Abstract Objective This study aimed to evaluate the role of 2-Deoxy-D-Glucose (2-DG) in moderate to severe Coronavirus Disease 2019 (COVID-19) cases. Methodology…[...]

New-onset chronic musculoskeletal pain following COVID-19 infection fulfil the Fibromyalgia clinical syndrome criteria


Omar Khoja, Matthew Mulvey, Sarah Astill,  et. al. doi: https://doi.org/10.1101/2024.07.10.24310234 Abstract Background: New-onset chronic musculoskeletal (MSK) pain (> 3 months duration) is one of the commonest persistent symptoms of Post-COVID syndrome (PCS). There is emerging evidence that…[...]

Kansas City Attorney General’s legal report on the case against Pfizer


BY CARL HENEGHAN, 2024  PHARMA, VACCINES   We’ve extracted the main points from the Kansas City Attorney General’s legal report on the case against Pfizer that we first mentioned in Due Process—all quotes are…[...]